Company Overview

Oaktree Acquisition Corp. III Life Sciences (NASDAQ: OACC) is a special purpose acquisition company (SPAC) formed to identify, evaluate, and complete a business combination within the healthcare and life sciences sectors. The company was sponsored by affiliates of Oaktree Capital Management, a global alternative investment manager, and was established as part of Oaktree’s broader strategy of leveraging sector-focused investment vehicles to pursue acquisition opportunities in industries with long-term growth potential. As a SPAC, OACC did not conduct traditional operating business activities prior to completing or pursuing a merger transaction; instead, its primary function was capital raising and acquisition execution.

The company focused on identifying targets across biotechnology, medical devices, diagnostics, healthcare services, and related life sciences technologies. Its positioning was based on access to Oaktree’s institutional investment platform, operational expertise, healthcare industry relationships, and capital markets experience. Public filings indicated that the company sought businesses with scalable platforms, differentiated intellectual property, or strong commercial growth profiles within healthcare innovation markets. Data regarding finalized operating activities or long-term standalone operations remains limited because SPAC entities are transitional corporate structures whose business model depends on consummating a merger transaction.

Business Operations

As a SPAC, OACC’s operations primarily consisted of identifying acquisition targets, conducting due diligence, negotiating merger agreements, and managing trust account capital raised through its public offering. Revenue generation prior to any business combination was generally limited to interest income earned on funds held in trust. The company’s operational structure was therefore materially different from that of a traditional operating enterprise with recurring commercial revenues or manufacturing activities.

OACC operated primarily from the United States and relied on the investment infrastructure and strategic support of Oaktree Capital Management and affiliated advisors. The company did not publicly report independent operating subsidiaries, manufacturing assets, or proprietary commercial technologies prior to a business combination. Its principal assets consisted of cash and investments held in a trust account following its IPO. Public disclosures also emphasized management’s experience in healthcare investing, corporate finance, and transaction execution as core strategic resources supporting acquisition efforts.

Strategic Position & Investments

OACC’s strategic direction centered on pursuing merger opportunities in the healthcare and life sciences industries, particularly businesses positioned to benefit from demographic trends, healthcare innovation, precision medicine, and increased demand for advanced therapeutic and diagnostic solutions. Management disclosures emphasized interest in companies with defensible intellectual property, scalable commercial models, and experienced management teams capable of operating in regulated healthcare environments.

The company’s strategic advantage was tied closely to the broader capabilities of Oaktree Capital Management, including institutional capital access, restructuring expertise, private equity experience, and relationships within healthcare investment networks. OACC did not publicly disclose a broad portfolio of operating subsidiaries or independent investment holdings because SPAC entities typically remain acquisition-focused until completing a merger. Information regarding certain proposed or potential transaction discussions may remain incomplete or subject to regulatory confidentiality obligations. Data inconclusive based on available public sources regarding finalized long-term portfolio operations independent of any completed business combination.

Geographic Footprint

OACC was headquartered in the United States and traded publicly on the Nasdaq exchange. Its acquisition mandate was primarily focused on North American healthcare and life sciences opportunities, though company filings indicated flexibility to evaluate international targets where strategic value and regulatory feasibility aligned with shareholder interests.

Through its affiliation with Oaktree Capital Management, the company indirectly benefited from a broader global investment presence spanning North America, Europe, and parts of Asia-Pacific. However, OACC itself did not operate extensive international commercial facilities or regional business units prior to completing a merger transaction. Its geographic influence was therefore principally tied to capital markets participation and target evaluation activities rather than direct operational infrastructure.

Leadership & Governance

OACC’s leadership structure reflected its relationship with experienced investment and healthcare professionals associated with Oaktree Capital Management and related advisory networks. Governance responsibilities focused on transaction oversight, regulatory compliance, capital stewardship, and identification of suitable acquisition targets within the life sciences and healthcare sectors. The company’s strategic philosophy emphasized disciplined underwriting, risk management, and long-term value creation consistent with Oaktree’s broader investment approach.

Key executives and directors publicly associated with the company included:

• John Frank – Chief Executive Officer
• Craig A. Jacobson – Chairman
• Matthew Boren – Chief Financial Officer
• Richard N. Massey – Director
• John M. Sullivan – Director

Leadership disclosures in public filings highlighted expertise in private equity, distressed investing, healthcare finance, mergers and acquisitions, and public company governance. The company’s governance framework followed standard SPAC practices, including oversight by an independent board and compliance obligations under SEC filings and Nasdaq listing standards.